Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1722802

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Covid-19 Inquiry
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Prime Minister's Written Statement of 18 July 2024 on the UK Covid-19 Inquiry Module 1 Report, HCWS11, whether the Prime Minister's personal commitment to each and every family who lost loved ones includes those who lost loved ones as a result of a Covid-19 vaccine.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	1179
answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered // answering member 1506 label Biography information for Andrew Gwynne
tabling member	242 label Biography information for Sir Christopher Chope

1722822

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the supply of pancreatic enzyme replacement therapies for people with cystic fibrosis.
tabling member constituency	South Holland and The Deepings
tabling member printed	Sir John Hayes
uin	1189
answer	answer is ministerial correction date of answer 26/07/2024 answer text <p>The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.</p><p>We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.</p><p>We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 26/07/2024 08:59:36 answering member 4444 label Biography information for Karin Smyth
tabling member	350 label Biography information for Sir John Hayes

1722832

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospices: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much grant funding each Integrated Care Board in England is providing for hospice funding for (a) children's and (b) other hospices over the 2024-25 financial year.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	1180
answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered // answering member 4359 label Biography information for Stephen Kinnock
tabling member	242 label Biography information for Sir Christopher Chope

1722864

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Palliative Care: Integrated Care Boards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the performance of Integrated Care Boards in England in fulfilling their duty to commission palliative and end of life care.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	1181
answer	answer is ministerial correction date of answer // answer text <p>The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered // answering member 4359 label Biography information for Stephen Kinnock
tabling member	242 label Biography information for Sir Christopher Chope

1722976

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Insurance: Private Sector
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of fee setting and de-recognition procedures on the (a) cost and (b) availability of private medical insurance.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	1183
answer	answer is ministerial correction date of answer 26/07/2024 answer text <p>Insurers make commercial decisions about pricing and the terms of cover they offer based on their assessment of the relevant risks. This is usually informed by the insurer’s claims experience and other industry-wide statistics. The respective capabilities of insurers to assess risk is a key element on which they compete, and the Government does not intend to intervene in these commercial decisions, as this could damage competition in the market. This competition is important and should lead to better products and lower prices for consumers overall.</p><p>Price is an important factor on which insurers compete to win customers, and that competition should push insurers to continuously improve their assessment of risks in order to lower prices and create better products for consumers. The Government intervening in insurance markets could damage that competition and, therefore, we do not generally intervene in the commercial pricing decisions of insurers.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 26/07/2024 08:18:15 answering member 4444 label Biography information for Karin Smyth
tabling member	242 label Biography information for Sir Christopher Chope

1723011

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) diagnosis, (b) treatment and (c) awareness of Myalgic Encephalomyelitis (ME) in the NHS.
tabling member constituency	Dudley
tabling member printed	Sonia Kumar
uin	1395
answer	answer is ministerial correction date of answer 25/07/2024 answer text <p>The Department, through the National Institute for Health and Care Research (NIHR), provides funding for research projects which aim to understand the underlying causes of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and find new treatments for the condition. For example, the NIHR, together with the Medical Research Council, have funded the world’s largest genome-wide association study of ME/CFS. This £3.2 million study, termed DecodeME, will analyse samples from 25,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. By helping us to understand ME/CFS better, this research has the potential to lead to new treatments for the condition.</p><p>Integrated care boards (ICBs) are responsible for commissioning specialist ME/CFS services that meet the needs of their population, subject to local prioritisation and funding. The process of commissioning services should take into account best practice guidance such as the National Institute for Health and Care Excellence’s (NICE) guidance on ME/CFS diagnosis and management, published in October 2021.</p><p>It is the duty of clinicians to keep themselves appraised of best practice, in particular guidance issued by the NICE. Whilst guidelines are not mandatory, clinicians and commissioners are expected to take them fully into account when designing services to meet the needs of their local population. The NICE promotes its guidance via its website, newsletters, and other media.</p><p>In October 2023, the British Association of Clinicians in ME/CFS published the ME/CFS National Services Survey. This report provides insight into the services being delivered for adults, children, and young people with ME/CFS.</p><p>The Department has been working with NHS England to develop an e-learning course on ME/CFS for healthcare professionals, to support staff to be able to provide better care and improve patient outcomes. This has involved feedback and input from patients. The Medical Schools Council will promote the NHS England e-learning package on ME/CFS to all United Kingdom medical schools, and encourage medical schools to provide undergraduates with direct patient experience of ME/CFS. A decision on next steps on ME/CFS at the national level will be taken in the coming weeks.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 25/07/2024 16:24:15 answering member 1506 label Biography information for Andrew Gwynne
tabling member	5274

1723013

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Shingles: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of offering shingles vaccines to everyone aged 60 and over.
tabling member constituency	Ealing Southall
tabling member printed	Deirdre Costigan
uin	1397
answer	answer is ministerial correction date of answer 26/07/2024 answer text <p>From September 2023, the routine shingles vaccination programme changed from the Zostavax vaccine to the more effective two dose Shingrix vaccine, to better protect individuals from the effects of shingles, provide better clinical outcomes, and reduce pressures on the health system. As a result, almost 1 million more people became eligible for the shingles vaccination.</p><p> </p><p>When a vaccination programme is expanded, decisions must be made regarding who to offer the vaccine to first. These decisions are based on advice given by the Joint Committee on Vaccination and Immunisation (JCVI), and include evidence on the impact of the vaccine in different age groups as well as the capacity of the National Health Service to deliver the vaccination programme alongside other important healthcare priorities.</p><p> </p><p>The expansion of the shingles programme currently includes those turning 65 years old on or after 1 September 2023, as well as those aged 50 years old and over who are at increased risk of serious complications. Phasing the roll-out of the shingles vaccination over time to everyone 60 years old and over is in line with the JCVI’s recommendation and maximises cost effectiveness and population benefit, ensures consistent messaging over time to maximise coverage, and takes account of NHS capacity, all while being consistent with the approach taken by all four nations in the United Kingdom. This is a newly expanded programme and anyone unsure if they are eligible for the shingles vaccination should check online, on the NHS.UK website, or should speak to their general practice.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 26/07/2024 13:35:29 answering member 1506 label Biography information for Andrew Gwynne
tabling member	5075

1723068

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon.
tabling member constituency	Redditch
tabling member printed	Chris Bloore
uin	1452
answer	answer is ministerial correction date of answer 26/07/2024 answer text <p>The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.</p><p>We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.</p><p>We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 26/07/2024 08:52:51 answering member 4444 label Biography information for Karin Smyth
tabling member	5109

1723093

registered interest
date	23/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sodium Valproate and Surgical Mesh Implants: Compensation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the recommendations of England’s Patient Safety Commissioner in the 'Hughes Report' on the sodium valproate and mesh implant scandals; when they intend to respond to that report; and when they anticipate the first payments arising under the recommended redress scheme may be made.
tabling member printed	Lord Kamall
uin	HL259
answer	answer is ministerial correction date of answer 26/07/2024 answer text <p>The Government is considering the recommendations of The Hughes Report, and to prevent future harm, the Medicines and Healthcare products Regulatory Agency, NHS England, and others have taken action to strengthen oversight of valproate prescribing and mesh procedures. For example, nine specialist mesh centres are in operation across England, ensuring that women with complications of mesh inserted for urinary incontinence and vaginal prolapse get the right support in every region, and we have maintained the national pause on the use of pelvic mesh, which has been in place since July 2018.</p> answering member printed Baroness Merron question first answered 26/07/2024 12:34:40 answering member 347 label Biography information for Baroness Merron
tabling member	4909 label Biography information for Lord Kamall

1722436

registered interest
date	22/07/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to roll-out self-sampling cervical cancer tests.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	953
answer	answer is ministerial correction date of answer 24/07/2024 answer text <p>A recently published YouScreen study provides evidence on offering a self-sampling test to non-attenders in the NHS Cervical Screening Programme. The UK National Screening Committee (UK NSC) plans to review this evidence and make a recommendation by the end of the year.</p><p>In addition, an in-service evaluation is being commissioned by the National Institute for Health and Care Research to determine whether self-sampling could be offered as an option to everyone eligible for cervical screening. The findings from this evaluation will be used to inform any recommendations made by the UK NSC.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 24/07/2024 09:44:09 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4131 label Biography information for Jim Shannon